Latest Articles about HALO

Mid-Afternoon Market Update: Optimer Falls as Halozyme Rockets Upwards

Jake L'Ecuyer — Thu, 16 May 2013 23:35:35 Z

Toward the end of trading Thursday, the Dow was down 0.10 percent to 15,259.91, while the NASDAQ rose 0.13 percent to 3,476.15. The S&P traded down, falling 0.23 percent to 1,654.47.

Mid-Day Market Update: US Stocks Fluctuate, Cisco Systems Up on Better-than-Expected Earnings

Jake L'Ecuyer — Thu, 16 May 2013 21:38:44 Z

Midway through trading Thursday, the Dow was up 0.05 percent to 15,282.91, while the NASDAQ rose 0.05 percent to 3,477.15. The S&P traded down, falling 0.08 percent to 1,657.47. Top

ViroPharma Reports Loss in 1Q - Analyst Blog

Zacks Equity Research — Thu, 02 May 2013 21:53:09 Z

ViroPharma Inc.'s ( VPHM ) first quarter 2013 adjusted loss (excluding special items but including stock-based compensation) came in at 7 cents per share compared to year-ago earnings

Market Wrap for Friday, March 22: Stocks Rise on Hopes of Bailout Deal for Cyprus

Scott Rubin — Sat, 23 Mar 2013 00:17:11 Z

The U.S. stock market closed out a choppy week with a gain as policymakers in Cyprus were in talks with EU officials to secure a bailout for the Mediterranean island which is facing a banking

Mid-Day Market Update: Micron Surges On Upbeat Revenue, Informatica Declines

Jake L'Ecuyer — Fri, 22 Mar 2013 21:23:02 Z

Midway through trading Friday, the Dow traded up 0.52 percent to 14,495.91 while the NASDAQ gained 0.45 percent to 3,237.05. The S&P also rose, gaining 0.55 percent to 1,554.33. Index

ViroPharma Tops on All Fronts - Analyst Blog

Zacks Equity Research — Fri, 01 Mar 2013 02:38:01 Z

ViroPharma Inc.'s ( VPHM ) fourth quarter 2012 adjusted earnings (including stock-based compensation) of 3 cents per share were above the Zacks Consensus Estimate of a penny but

Largest option buying in equities so far

David Russell — Wed, 30 Jan 2013 21:14:14 Z

Nearing the halfway mark in today's session, here are the individual equity names with the most call and put buying on optionMONSTER's ActionTracker data system. Staples (SPLS): More than

One Biotech Stock Investors are Unfairly Ignoring

Tim Parker — Tue, 15 Jan 2013 19:00:00 Z

Shares of biotech company Halozyme Therapeutics (NASDAQ: HALO ) were unchanged in pre-market trading on Tuesday following Monday's gain of more than 15 percent. Investors bid up the stock

Upbeat 2013 from ViroPharma - Analyst Blog

Zacks Equity Research — Wed, 09 Jan 2013 03:29:01 Z

ViroPharma Incorporated ( VPHM ) recently provided guidance for 2013. ViroPharma expects net product sales between $450 million and $475 million in 2013 on a worldwide basis.

Pfizer Signs a Couple of Deals - Analyst Blog

Zacks Equity Research — Thu, 27 Dec 2012 01:50:01 Z

Pfizer ( PFE ) recently entered into two deals. While one deal was signed with biopharma company Halozyme Therapeutics, Inc. ( HALO ), the second deal was signed with clinical

Mid-Afternoon Update: Herbalife Takes a Bigger Beating, Markets Still Red

Benzinga — Sat, 22 Dec 2012 01:54:30 Z

Toward the end of trading Friday, the Dow traded down 0.90 percent to 13,191.24 while the NASDAQ fell 1.02 percent to 3,019.21. The S&P also fell, decreasing 0.85 percent to 1,431.42.

Pre-Market Most Active for Dec 21, 2012 : BAC, RIMM, ITUB, QQQ, NOK, TOT, SIRI, C, FB, NJ, HALO, ASCA

NASDAQ.com News — Fri, 21 Dec 2012 18:40:01 Z

The NASDAQ 100 Pre-Market Indicator is down -28.92 to 2,664.63. The total Pre-Market volume is currently 7,875,926 shares traded. The following are the most active stocks for the

ViroPharma Presents Cinryze Data - Analyst Blog

Zacks Equity Research — Thu, 15 Nov 2012 01:00:01 Z

ViroPharma Inc. ( VPHM ) presented promising data on Cinryze at the American College of Allergy, Asthma and Immunology's (ACAAI) annual congress. Data was presented from a post marketing

Revenues Fall at ViroPharma - Analyst Blog

Zacks Equity Research — Mon, 29 Oct 2012 22:27:00 Z

ViroPharma Inc.'s ( VPHM ) third quarter 2012 adjusted earnings (including stock based compensation) of 3 cents per share were slightly above the Zacks Consensus Estimate of 2 cents but

Pertaining to Relief for ViroPharma - Analyst Blog

Zacks Equity Research — Tue, 25 Sep 2012 23:36:01 Z

The US Food and Drug Administration (FDA) recently informed ViroPharma Incorporated ( VPHM ) that the company may continue with its clinical studies of the subcutaneous administration of